Block Listing Application to AIM

Diaceutics PLC

02 October 2023

 

Block Listing Application to AIM

Belfast and London, 2 October 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today announces an application has been made to AIM for a block listing of 1,500,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following Company's share schemes:

·	the UK and Global Share Incentive Plan for employees (the "SIP"); and
·	the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

The block listing is expected to become effective on or around 6 October 2023. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligation under AIM Rule 29.

At the time of this announcement, Diaceutics has 84,472,431 Ordinary Shares in issue. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information from Diaceutics PLC, please contact:

Enquiries: 

Diaceutics PLC	Tel: [phone]
Nick Roberts, Chief Financial Officer	[e-mail]
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Nick Harland
Kate Hanshaw
Alma	Tel: [phone]
Caroline Forde	[e-mail]
Matthew Young
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®

 

END